ArticleClinical journal of the American Society of Nephrology : CJASN2008
D-dimer level and the risk for thrombosis in systemic lupus erythematosus.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Comparison of aspirin and rivaroxaban for the prevention of pulmonary embolism and deep vein thrombosis in high thrombotic risk patients with systemic lupus erythematosus: study protocol for a multicentre, prospective, randomised controlled trial.Lupus science & medicine · 2026Article
- Fibrin Monomer and Systemic Lupus Erythematosus Reactivation During Pregnancy: A Retrospective Study.Diseases (Basel, Switzerland) · 2025Article
- Renal damage and old age: risk factors for thrombosis in patients with ANCA-associated vasculitis.Thrombosis journal · 2024Article
- A nested case-control study investigating short-term prognosis, clinical and imaging features in acute ischemic stroke patients with systemic lupus erythematosus.Acta neurologica Belgica · 2023Article
- An interaction between the inflammatory condition and the hypercoagulable condition occurs in primary Sjögren syndrome.Clinical rheumatology · 2023Article
- Response to belimumab in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a case-based review.Clinical rheumatology · 2022Review
- Autoimmune Thrombocytopenia in SLE and COVID-19.European journal of case reports in internal medicine · 2021Article
- Acute pulmonary embolism multimodality imaging prior to endovascular therapy.The international journal of cardiovascular imaging · 2021Review
- Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis.Arthritis research & therapy · 2019Article
- Clinical features and prognosis of patients with thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a review of 25 cases.Italian journal of pediatrics · 2019Article
- Clinical features and prognostic factors of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a literature review of 105 cases from 1999 to 2011.Clinical rheumatology · 2014Review
- Differential diagnosis of glomerular disease: a systematic and inclusive approach.American journal of nephrology · 2013Review
- An approach to validating criteria for proteinuric flare in systemic lupus erythematosus glomerulonephritis.Arthritis and rheumatism · 2011Article
- Acute systemic lupus erythematosus on the acute medical take: are we missing anything?Clinical medicine (London, England) · 2011Article
- Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care?Nephron. Clinical practice · 2011Review
- Predicting thrombosis in systemic lupus erythematosus.Nature clinical practice. Nephrology · 2009Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
objectivesPatients who have systemic lupus erythematosus (SLE) and manifest antiphospholipid antibodies (APA) are at increased risk for thrombosis; however, it is difficult to predict who will clot. This study tested the hypothesis that peak D-dimer level measured routinely during follow-up identifies whether a hypercoagulable state is developing and, therefore, the patient is at increased risk for thrombosis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: One hundred consecutive patients who had SLE with recurrent activity (71% renal SLE) and were evaluated for or enrolled in the Ohio SLE Study were studied. D-dimer testing was done annually and usually at SLE flare or other serious illness. When D-dimer was elevated, evaluation for thrombosis (large vessel, small vessel, or Libman-Sacks) was undertaken. Mean follow-up was 37.5 +/- 15 SD months.
resultsOf those with peak D-dimer <0.5 microg/ml (n = 46), 0% thrombosed, 33% had APA. Of those with peak D-dimer 0.5 to 2.0 microg/ml (n = 19), 6% thrombosed, 44% had APA. Of those with peak D-dimer >2.0 microg/ml (n = 36), 42% thrombosed, 76% had APA. The most common causes of elevated D-dimer in the absence of demonstrable thrombosis were SLE flare and systemic infection. D-dimer levels were usually elevated for several months before thrombosis.
conclusionsPatients with SLE and normal D-dimer levels are at low risk for thrombosis, irrespective of APA status. Those with persistent unexplained elevated D-dimer levels, particularly when >2.0 microg/ml, are at high risk for thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.